TEVA PHARMACEUTICAL INDUSTRIES LTD

Teva Pharmaceutical Industries develops, manufactures, and distributes generic medicines, specialty pharmaceuticals, and biopharmaceutical products across the United States, Europe, Israel, and international markets. The company produces medications in multiple dosage forms including tablets, capsules, injectables, inhalants, and transdermal patches, with particular focus on sterile products, high-potency drugs, and cytotoxic substances. Teva operates an active pharmaceutical ingredient business and provides contract manufacturing services to other pharmaceutical companies.

The company maintains a diversified portfolio spanning multiple therapeutic areas. Branded specialty products include COPAXONE for relapsing multiple sclerosis, AJOVY for migraine prevention, and AUSTEDO for Huntington's disease-associated chorea and tardive dyskinesia. Respiratory products include ProAir RespiClick, QVAR RediHaler, DuoResp Spiromax, and AirDuo RespiClick. Additional offerings encompass BENDEKA and TREANDA for hematologic malignancies, UZEDY for schizophrenia, and CINQAIR/CINQAERO for eosinophilic conditions. Over-the-counter brands include SUDOCREM and FLEGAMINA. The company also operates an out-licensing platform offering products to other pharmaceutical manufacturers.

Founded in 1901 and headquartered in Tel Aviv-Yafo, Teva employs approximately 31,173 full-time employees globally. The company maintains collaboration and licensing agreements with MedinCell, Sanofi, Alvotech, and Biolojic Design.